Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae

The next-generation aminoglycoside plazomicin, in development for infections due to multidrug-resistant (MDR) Enterobacteriaceae, was evaluated alongside comparators for bactericidal activity in minimum bactericidal concentration (MBC) and time-kill (TK) assays against MDR Enterobacteriaceae isolate...

Descripción completa

Detalles Bibliográficos
Autores principales: Thwaites, M., Hall, D., Shinabarger, D., Serio, A. W., Krause, K. M., Marra, A., Pillar, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105851/
https://www.ncbi.nlm.nih.gov/pubmed/29866876
http://dx.doi.org/10.1128/AAC.00236-18
Descripción
Sumario:The next-generation aminoglycoside plazomicin, in development for infections due to multidrug-resistant (MDR) Enterobacteriaceae, was evaluated alongside comparators for bactericidal activity in minimum bactericidal concentration (MBC) and time-kill (TK) assays against MDR Enterobacteriaceae isolates with characterized aminoglycoside and β-lactam resistance mechanisms. Overall, plazomicin and colistin were the most potent, with plazomicin demonstrating an MBC(50/90) of 0.5/4 μg/ml and sustained 3-log(10) kill against MDR Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp.

Ejemplares similares